Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study
| Autor: | C Michelassi, A. Nicolini, L. Anselmi, Angelo Carpi |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Time Factors medicine.medical_treatment Salvage therapy Breast Neoplasms Asymptomatic Breast cancer Biomarkers Tumor medicine Humans Survival analysis Aged Retrospective Studies Aged 80 and over Salvage Therapy Chemotherapy business.industry Reproducibility of Results Retrospective cohort study Middle Aged medicine.disease Combined Modality Therapy Surgery Menopause Treatment Outcome Oncology Chemotherapy Adjuvant Female Radiotherapy Adjuvant medicine.symptom business Mastectomy Research Article Follow-Up Studies |
| Zdroj: | Scopus-Elsevier British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/bjc.1997.515 |
| Popis: | Between 1977 and 1993, 384 breast cancer patients were followed up post-operatively every 4 or 6 months with a serum tumour marker panel (CEA-TPA-CA15-3) and the usual imaging techniques. Twenty-eight patients were treated 13.5 +/- 10 months (mean +/- s.d.) before the clinical and/or radiological occurrence of distant metastases that were suspected because of an increase in the tumour markers (patients treated 'early'). Their outcome was compared with that of 22 similar patients who were treated only after a definite radiological diagnosis was achieved (patients treated 'not early'). The median survivals from mastectomy and salvage treatment were also compared for the two groups. The groups were similar for all the major prognostic factors (menopause, staging, hormone dependency). In the group treated 'early', the lead time from the tumour marker increase to the clinical and radiological signs of metastases was significantly longer than that of the group not treated 'early' (13.5 +/- 10 vs 3.4 +/- 2.8 months respectively; P < 0.001 by unpaired t-test). For patients treated 'early', the survival curves up to 30 months after salvage treatment and up to 72 months after mastectomy showed greater survival than those for the patients treated later (42.9% vs 13.6% and 42.9% vs 22.7% respectively; P = 0.04 in both instances). These data suggest that treatment triggered by rising tumour markers before clinical and/or radiological appearance of distant metastases can be useful in prolonging both the asymptomatic interval and the duration of response of some relapsed patients. Randomized prospective trials must be encouraged to confirm these data and to better evaluate the effect on the disease-free survival (DFS) and overall survival (OS) of 'early' salvage treatment protocols. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|